1 FEV1 (% predicted) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
1.1 Children |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.2 Adults |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
1.3 Children and Adults |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2 Daily dose of oral prednisiolone (mg) |
2 |
63 |
Mean Difference (IV, Fixed, 95% CI) |
‐6.31 [‐8.68, ‐3.94] |
2.1 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
2.2 Adults |
2 |
63 |
Mean Difference (IV, Fixed, 95% CI) |
‐6.31 [‐8.68, ‐3.94] |
2.3 Children and Adults |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3 Reduction in daily dose of oral prednisolone (mg) |
2 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.91 [‐5.88, ‐3.94] |
3.1 Children |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.2 Adults |
2 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.91 [‐5.88, ‐3.94] |
3.3 Children and Adults |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4 Daytime asthma symptom score |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
4.1 Children |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.2 Adults |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
4.3 Children and Adults |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5 Night‐time asthma symptom score |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
5.1 Children |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.2 Adults |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.3 Children and Adults |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Plasma cortisol (mmol/L) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
6.1 Children |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6.2 Adults |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6.3 Children and Adults |
0 |
|
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7 Oropharyngeal side‐effects |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
7.1 Children |
0 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.2 Adults |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.3 Children and Adults |
0 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8 Oropharyngeal Candidiasis (No. of patients) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
8.1 Children |
0 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.2 Adults |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.3 Children and Adults |
0 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
9 Discontinuation of oral steroids (No. of patients) |
4 |
152 |
Risk Ratio (M‐H, Random, 95% CI) |
6.95 [2.79, 17.34] |
9.1 Children |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.2 Adults |
4 |
152 |
Risk Ratio (M‐H, Random, 95% CI) |
6.95 [2.79, 17.34] |
9.3 Children and Adults |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |